CTRN
Citi Trends, Inc.
CTRN has a slight edge over NIO overall, supported by stronger modeled upside and lower modeled downside.
NIO
NIO Inc.
NIO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CTRN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CTRN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Stable | |
| Unavailable |
NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
CTRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $3.31 | -92% |
| Fair | 10x | $8.73 | -80% |
| Forward | 19x | $43.05 | — |
| Expensive | 46x | $39.40 | -8.5% |
| Current | 50x | $43.05 | — |
Historical ranges are pointers, not guarantees.
CTRN's PE is in its expensive range at 50x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.
NIO PE Valuation
NIO has no meaningful PE right now: it lost money over the past year.
CTRN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CTRN, with profitability improving.
NIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect NIO's losses to shrink, with revenue growing.
CTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +170% |
| Q3 2026 | $0.86 | +$2.85 |
| Q2 2026 | $1.43 | +$6.09 |
| Q1 2026 | $0.63 | +$5.82 |
| Q4 2025 | -$1.99 | +$1.07 |
| Q3 2025 | -$1.99 | +$0.68 |
| Q2 2025 | -$4.66 | -$3.59 |
| Q1 2025 | -$5.19 | -$3.73 |
| Q4 2024 | -$3.06 | -$2.04 |
CTRN has the edge over NIO on earnings quality, reporting a profit while its opponent remains loss making.
NIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.29 | +$1.45 |
| Q1 2026 | -$0.60 | +$1.16 |
| Q4 2025 | -$1.06 | +$0.60 |
| Q3 2025 | -$1.59 | +$0.02 |
| Q2 2025 | -$1.74 | -$0.10 |
| Q1 2025 | -$1.76 | +$0.06 |
| Q4 2024 | -$1.66 | +$0.21 |
| Q3 2024 | -$1.61 | +$0.32 |
NIO is still losing money, but far less than before: $0.29 per share over the past year, against $1.93 at its worst in late 2023.
CTRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211.6M | +11% |
| Q2 2026 | $230.9M | +14% |
| Q1 2026 | $230.4M | +9.1% |
| Q4 2025 | $197.1M | +10% |
| Q3 2025 | $190.8M | +8% |
| Q2 2025 | $201.7M | +8.3% |
| Q1 2025 | $211.2M | -1.9% |
| Q4 2024 | $179.1M | -0.3% |
CTRN's revenue is recovering but still below its 2021 peak: $212M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | -2.7 points |
| Q2 2026 | 3.2% | +3 points |
| Q1 2026 | 3.1% | +2.6 points |
| Q4 2025 | -3.7% | +1.2 points |
| Q3 2025 | 1.8% | +16 points |
| Q2 2025 | 0.2% | +4 points |
| Q1 2025 | 0.6% | -1.3 points |
| Q4 2024 | -4.9% | -1.6 points |
CTRN has the edge over NIO on profitability, with a higher operating margin.
NIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +69% |
| Q1 2026 | $3.8B | +112% |
| Q4 2025 | $5.2B | +76% |
| Q3 2025 | $3.3B | +17% |
| Q2 2025 | $2.9B | +9% |
| Q1 2025 | $1.8B | +21% |
| Q4 2024 | $3B | +15% |
| Q3 2024 | $2.8B | -2.1% |
NIO has the edge over CTRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.1% | +24 points |
| Q1 2026 | -1.2% | +52 points |
| Q4 2025 | 2.3% | +33 points |
| Q3 2025 | -16% | +12 points |
| Q2 2025 | -26% | +4 points |
| Q1 2025 | -53% | +1.1 points |
| Q4 2024 | -31% | +8.1 points |
| Q3 2024 | -28% | -2.6 points |
NIO's operating margin was −2.1% last quarter, up 24 points from the same quarter a year ago.
CTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24M | -$22.2M |
| Q2 2026 | $15M | +$28.1M |
| Q1 2026 | $14.7M | -44% |
| Q4 2025 | $767K | +$21.2M |
| Q3 2025 | -$1.7M | -205% |
| Q2 2025 | -$13.1M | +$8.1M |
| Q1 2025 | $26M | +30% |
| Q4 2024 | -$20.4M | -$12.8M |
CTRN's free cash flow has turned positive after four years mostly in the red: $6M over the past year.
NIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$2.1B |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | +$391.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$2.1B | +$73.9M |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$391.3M | -386% |
| Q2 2024 | -$2.2B | +$337.9M |
NIO's free cash flow was $0 over the past year, against −$2.5B the year before.
CTRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.2x | Net Cash |
| Q2 2026 | -2.7x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -3.2x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2024 | -27.2x | Net Cash |
| Q4 2023 | -20.2x | Net Cash |
| Q3 2023 | -1.6x | Net Cash |
CTRN has more cash than debt.
NIO Net Leverage
NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 6.0 | Oversold |
CTRN's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
NIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 6.9 | Oversold |
NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
CTRN PE vs Consumer Cyclical Sector
| Metric | CTRN | Sector median | Relative |
|---|---|---|---|
| PE | 50x | 18x | 178% above |
| PE % | 86 | 47 | 39 pts above |
CTRN is trading at 50x earnings, a 178% premium to the Consumer Cyclical sector's median of 18x.
NIO PE vs Consumer Cyclical Sector
NIO has no meaningful PE right now: it lost money over the past year.
CTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 9.1% below |
| 20 week MA | $57.9 | 26% below |
| 50 week MA | $50.8 | 15% below |
| 100 week MA | $40.1 | 7.4% above |
| 200 week MA | $31.2 | 38% above |
CTRN has the edge over NIO on trend strength, trading above more of its moving averages.
NIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 9.2% below |
| 20 week MA | $4.01 | 24% below |
| 50 week MA | $4.81 | 37% below |
| 100 week MA | $4.85 | 37% below |
| 200 week MA | $6.03 | 49% below |
NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
CTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $47.4 | +108% |
| 2021 | $47.4 | $76.4 | +61% |
| 2022 | $76.4 | $27.6 | -64% |
| 2023 | $27.6 | $28.3 | +2.4% |
| 2024 | $28.3 | $26.9 | -5.1% |
| 2025 | $26.9 | $40.2 | +50% |
| 2026 YTD | $40.2 | $43.1 | +7.2% |
CTRN has the edge over NIO on returns for 2026, with the stronger performance.
NIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.42 | $45.8 | +1791% |
| 2021 | $45.8 | $30.5 | -33% |
| 2022 | $30.5 | $11.0 | -64% |
| 2023 | $11.0 | $9.07 | -17% |
| 2024 | $9.07 | $4.48 | -51% |
| 2025 | $4.48 | $5.10 | +14% |
| 2026 YTD | $5.10 | $3.05 | -40% |
NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.